Jeff Martin
Stock Analyst at Roth Capital
(3.66)
# 808
Out of 4,987 analysts
61
Total ratings
63.79%
Success rate
19.58%
Average return
Main Sectors:
Stocks Rated by Jeff Martin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NSP Insperity | Maintains: Buy | $85 → $74 | $50.38 | +46.88% | 9 | Aug 4, 2025 | |
| FC Franklin Covey Co. | Maintains: Buy | $30 → $27 | $19.75 | +36.71% | 8 | Jul 7, 2025 | |
| TACT TransAct Technologies | Maintains: Buy | $6 → $5 | $4.85 | +3.09% | 1 | May 14, 2025 | |
| PERI Perion Network | Upgrades: Buy | $9 → $14 | $9.83 | +42.42% | 8 | May 14, 2025 | |
| OSIS OSI Systems | Maintains: Buy | $224 → $245 | $235.44 | +4.06% | 16 | May 2, 2025 | |
| BGSF BGSF, Inc. | Maintains: Buy | $12 → $9 | $7.19 | +25.17% | 1 | Mar 20, 2025 | |
| BBSI Barrett Business Services | Maintains: Buy | $43 → $45 | $46.13 | -2.45% | 5 | Nov 7, 2024 | |
| HCKT The Hackett Group | Maintains: Buy | $29 → $30 | $19.82 | +51.36% | 6 | Nov 5, 2024 | |
| BWMN Bowman Consulting Group | Maintains: Buy | $47 → $43 | $42.91 | +0.21% | 5 | Aug 8, 2024 | |
| GLMD Galmed Pharmaceuticals | Initiates: Buy | $5,760 | $1.46 | +394,420.55% | 2 | Nov 15, 2017 |
Insperity
Aug 4, 2025
Maintains: Buy
Price Target: $85 → $74
Current: $50.38
Upside: +46.88%
Franklin Covey Co.
Jul 7, 2025
Maintains: Buy
Price Target: $30 → $27
Current: $19.75
Upside: +36.71%
TransAct Technologies
May 14, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $4.85
Upside: +3.09%
Perion Network
May 14, 2025
Upgrades: Buy
Price Target: $9 → $14
Current: $9.83
Upside: +42.42%
OSI Systems
May 2, 2025
Maintains: Buy
Price Target: $224 → $245
Current: $235.44
Upside: +4.06%
BGSF, Inc.
Mar 20, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $7.19
Upside: +25.17%
Barrett Business Services
Nov 7, 2024
Maintains: Buy
Price Target: $43 → $45
Current: $46.13
Upside: -2.45%
The Hackett Group
Nov 5, 2024
Maintains: Buy
Price Target: $29 → $30
Current: $19.82
Upside: +51.36%
Bowman Consulting Group
Aug 8, 2024
Maintains: Buy
Price Target: $47 → $43
Current: $42.91
Upside: +0.21%
Galmed Pharmaceuticals
Nov 15, 2017
Initiates: Buy
Price Target: $5,760
Current: $1.46
Upside: +394,420.55%